Divi''s Laboratories Ltd.

NSE: DIVISLAB BSE: 532488 SECTOR: Pharmaceuticals & Drugs  110k   1k   165

4179.40
-150.35 (-3.47%)
NSE: 21 Jan 03:59 PM

Price Summary

Today's High

₹ 4328.3

Today's Low

₹ 4137.8

52 Week High

₹ 5425.1

52 Week Low

₹ 3153.3

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

110949.94 Cr.

Enterprise Value

108808.28 Cr.

No. of Shares

26.55 Cr.

P/E

52.64

P/B

11.21

Face Value

₹ 2

Div. Yield

0.48 %

Book Value (TTM)

₹  372.89

CASH

2142.01 Cr.

DEBT

0.35 Cr.

Promoter Holding

51.95 %

EPS (TTM)

₹  79.39

Sales Growth

28.02%

ROE

23.57 %

ROCE

31.64%

Profit Growth

42.4 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Index Presence

The company is present in 38 Indices.

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year28.02%
3 Year21.23%
5 Year12.81%

Profit Growth

1 Year42.4%
3 Year31%
5 Year11.97%

ROE%

1 Year23.57%
3 Year21.13%
5 Year20.05%

ROCE %

1 Year31.64%
3 Year28.31%
5 Year26.9%

Debt/Equity

0

Price to Cash Flow

56.98

Interest Cover Ratio

1452.86187845304

CFO/PAT (5 Yr. Avg.)

0.916523493338073

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Dec 2021 51.95 0
Sep 2021 51.95 0
Jun 2021 51.95 0
Mar 2021 51.95 0
Dec 2020 51.95 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 30.9960915228358% for the Past 3 years.
  • The company has shown a good revenue growth of 21.2286757193128% for the Past 3 years.
  • The company has significantly decreased its debt by 33.28 Cr.
  • Company has been maintaining healthy ROE of 21.1294239745125% over the past 3 years.
  • Company has been maintaining healthy ROCE of 28.3088523909343% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 1452.86187845304.
  • The Company has been maintaining an effective average operating margins of 36.16004282504% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of 81.9949708452105 days.
  • Company has a healthy liquidity position with current ratio of 3.95429322258591.
  • The company has a high promoter holding of 51.95%.

 Limitations

  • The company is trading at a high PE of 52.64.
  • The company is trading at a high EV/EBITDA of 34.592.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021
Net Sales 1713.78 1656.48 1718.39 1950.16 1967.86
Total Expenditure 981.39 978.03 1019.04 1098.69 1149.27
Operating Profit 732.39 678.45 699.35 851.47 818.59
Other Income 13.64 19.68 22.85 35.55 19.11
Interest 0.11 0.22 0.18 0.24 0.17
Depreciation 60.89 67.95 69.84 73.01 77.09
Exceptional Items 0 0 0 0 0
Profit Before Tax 685.03 629.96 652.18 813.77 760.44
Tax 171.73 168.72 164.25 261.8 154.05
Profit After Tax 513.3 461.24 487.93 551.97 606.39
Adjusted EPS (Rs) 19.34 17.38 18.38 20.79 22.84

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Net Sales 4023.85 3815.94 4879.66 5310.57 6798.61
Total Expenditure 2584.97 2564.33 3029.59 3494.16 3977.73
Operating Profit 1438.88 1251.61 1850.07 1816.41 2820.88
Other Income 75.94 112.48 156.58 189.86 63.45
Interest 3.33 2.31 4.61 7.03 1.81
Depreciation 123.26 142.42 168.81 185.95 254.65
Exceptional Items 0 0 0 0 0
Profit Before Tax 1388.23 1219.36 1833.23 1813.29 2627.87
Tax 334.96 349.78 500.58 440.58 673.15
Net Profit 1053.27 869.58 1332.65 1372.71 1954.72
Adjusted EPS (Rs.) 39.68 32.76 50.2 51.71 73.64

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Equity and Liabilities
Share Capital 53.09 53.09 53.09 53.09 53.09
Total Reserves 5355.82 5906.56 6920.22 7263.6 9218.48
Borrowings 0 0 0 0 0
Other N/C liabilities 1418.95 1769.95 993.72 294.48 363.48
Current liabilities 655.84 640.49 832.52 1796.64 1704.78
Total Liabilities 7483.7 8370.09 8799.55 9407.81 11339.83
Assets
Net Block 1558.95 1995.88 2087.44 2776.26 3699.01
Capital WIP 443.57 119.76 491.91 919.69 710.62
Intangible WIP 0 0 0 0 0
Investments 8.37 7.37 554.62 7.37 7.37
Loans & Advances 1424.88 1688.04 1012.93 144.18 172.42
Other N/C Assets 8.78 5.13 5.16 5.44 9.21
Current Assets 4039.15 4553.91 4647.49 5554.87 6741.2
Total Assets 7483.7 8370.09 8799.55 9407.81 11339.83
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Profit from operations 1388.23 1219.36 1833.23 1813.29 2627.87
Adjustment 81.1 29.72 86.71 52.55 186.66
Changes in Assets & Liabilities -18.52 -215.81 -472.96 -211.4 -234.52
Tax Paid -301.7 -268.55 -482.92 -445.97 -632.96
Operating Cash Flow 1149.11 764.72 964.06 1208.47 1947.05
Investing Cash Flow -1137.41 -475.89 -684.24 -81.38 75.34
Financing Cash Flow 3.27 -314.17 -245.94 -1091.25 -33.97
Net Cash Flow 14.97 -25.34 33.88 35.84 1988.42

Corporate Actions

Investors Details

PARTICULARS Dec 2020% Mar 2021% Jun 2021% Sep 2021% Dec 2021%
Promoters 51.95 51.95 51.95 51.95 51.95
nilima motaparti 20.34 - - - -
divi satchandra ki... 20.34 20.34 20.34 20.34 -
nilima prasad divi - 20.34 20.34 20.34 20.34
satchandra kiran d... - - - - 20.34
murali krishna pra... 2.85 2.85 2.85 2.85 2.85
divi swarna latha 5.27 5.27 5.27 5.27 -
swarna latha divi - - - - 5.27
divis biotech priv... - - - - -
divi madhusudana r... 0.11 0.11 0.11 0.11 -
madhusudana rao di... - - - - 0.11
divi babu rajendra... - - - - -
babu rajendra pras... 0.01 0.01 - 0.01 0.01
babu rajendra pras... - - 0.01 - -
PARTICULARS Dec 2020% Mar 2021% Jun 2021% Sep 2021% Dec 2021%
Investors 48.05 48.05 48.05 48.05 48.05
reliance capital t... - - - - -
sbi mutual fund 4.84 4.69 4.49 4.49 4.78
axis mutual fund t... 3.03 3.14 3.37 3.64 3.78
qualified institut... 3.36 - 3.57 - -
life insurance cor... 1.15 1.15 1.15 1.39 2.03
government pension... 1.63 1.28 1.29 1.29 1.30
iepf 0.01 0.01 0.01 0.01 0.01

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Divi's Laboratories submits certificate7 Jan 2022, 10:35AM Divi's Laboratories reports 17% rise in Q2 consolidated net profit8 Nov 2021, 9:30AM Divis Laboratories informs about outcome of board meeting6 Nov 2021, 12:50PM Divi's Lab - Quaterly Results6 Nov 2021, 11:48AM Divi's Lab - Quaterly Results6 Nov 2021, 11:48AM Divi's Lab - Quaterly Results6 Nov 2021, 11:48AM Divi’s Laboratories informs about earnings conference call2 Nov 2021, 9:53AM Divis Laboratories informs about updates30 Aug 2021, 3:47PM Divi’s Laboratories reports 13% rise in Q1 consolidated net profit 9 Aug 2021, 12:21PM Divi’s Laboratories informs about newspaper publication21 Jul 2021, 3:41PM Divis Laboratories informs about annual secretarial compliance report1 Jun 2021, 10:04AM Divis Laboratories informs about manufacturing of molnupiravir API 26 May 2021, 5:06PM Divi's Laboratories informs about schedule of earnings conference call 22 May 2021, 12:23PM Divis Laboratories informs about closure of trading window31 Mar 2021, 11:35AM Divis Laboratories informs about certificate7 Jan 2021, 10:38AM Divi’s Laboratories to commence construction at unit-III Andhra Pradesh facility1 Dec 2020, 3:01PM Divi’s Laboratories board to approve unaudited financial results27 Oct 2020, 1:34PM Divis Laboratories informs about clarification regarding the news 16 Sep 2020, 10:34AM Divi’s Laboratories reports 80% rise in Q1 consolidated net profit10 Aug 2020, 11:15AM Divis Laboratories informs about certificate15 Jul 2020, 10:17AM

Divi''s Lab Stock Price Analysis and Quick Research Report. Is Divi''s Lab an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Divi''s Lab and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 1947.05 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Divi''s Lab has a Debt to Equity ratio of 0 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Divi''s Lab , the EPS growth was 42.3985643730928 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Divi''s Lab has OPM of 41.4920108669272 % which is a good sign for profitability.
     
  • ROE: Divi''s Lab have a healthy ROE of 23.5675109987425 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Divi''s Lab

X